Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
104,661,494
-
Total 13F shares
-
73,838,140
-
Share change
-
+5,931,411
-
Total reported value
-
$1,363,055,604
-
Put/Call ratio
-
35%
-
Price per share
-
$18.46
-
Number of holders
-
189
-
Value change
-
+$97,419,982
-
Number of buys
-
110
-
Number of sells
-
73
Institutional Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) as of Q4 2022
As of 31 Dec 2022 Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) had 189 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 73,838,140 shares of stock of the company.
Largest 10 holders included Capital World Investors, BlackRock Inc., Palo Alto Investors LP, JPMORGAN CHASE & CO, Polar Capital Holdings Plc, VANGUARD GROUP INC, FRANKLIN RESOURCES INC, STATE STREET CORP, JENNISON ASSOCIATES LLC, and FMR LLC.
This table shows 189 institutional shareholders of the security as of 31 Dec 2022.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.